Datamonitor conducted a study that gives generic drug makers something to look forward to as drugs such as Zoloft and Zyrtec lose patent protection in the next five years. Analysts believe seven generic drug makers will post average annual earnings increases of 19% over the next three to five years: Alpharma; Andrx; Barr Pharmaceuticals; Mylan Laboratories; Pharmaceutical Resources; Teva Pharmaceutical Industries; and Watson Pharmaceuticals.

Full Story:

Related Summaries